Metropolis Healthcare acquires Ambika Pathology, expands Western Maharashtra presence

Metropolis Healthcare Limited announced the acquisition of Dr. R.S. Patil's Ambika Pathology Laboratory in Kolhapur, effective September 18, 2025. This marks Metropolis' fourth acquisition in the last 10 months and is part of its strategy to build strong regional clusters and enhance access to advanced diagnostics across India. Ambika Pathology, a NABL-accredited facility, will be developed into a mini regional reference lab, offering over 4,000 advanced and specialty diagnostics.

The acquisition was executed via a business transfer agreement (BTA), with operations now under Metropolis Healthcare Limited. This move significantly bolsters Metropolis’s presence in Western Maharashtra, where it already operates 19 laboratories and over 200 patient service centers across multiple cities. The company highlighted Maharashtra's contribution of nearly 40% to its total revenues.

Ambika Pathology, established in 1995, operates a central laboratory supported by 12 patient touchpoints and generates approximately 75% of its revenue from B2C walk-in patients. The integration is expected to enhance Metropolis' specialized diagnostics capabilities in the region and contribute to its goal of delivering world-class diagnostics with faster, more accurate insights.